Stocks Overview

LAST PRICE
0.1720
TODAY'S CHANGE (%)
Trending Up0.0021 (1.2360%)

Bid / Lots
0.1720/ 1
Ask / Lots
0.1722/ 4
Open / Previous Close
0.1633 / 0.1699
Day Range
Low 0.1563
High 0.1800
52 Week Range
Low 0.0512
High 1.2200
Volume
13,609,550
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TSX Comp
TSX Venture
DJIA
S&P 500
NASDAQ

Price Comparison Graph. See accessible table below

1 Day Comparison Chart Accessibility Table. Wednesday's close: 0.1699
Time	Volume	JAGX
09:32 ET	199039	0.1637
09:34 ET	244859	0.1628
09:36 ET	575776	0.1621
09:38 ET	165306	0.1612
09:39 ET	249731	0.1592
09:41 ET	310259	0.1563
09:43 ET	282265	0.1589
09:45 ET	185862	0.1621
09:48 ET	189624	0.1623
09:50 ET	150018	0.1619
09:52 ET	44073	0.1613
09:54 ET	46947	0.161
09:56 ET	73683	0.1614
09:57 ET	85875	0.1617
09:59 ET	29665	0.1618
10:01 ET	93976	0.1605
10:03 ET	120614	0.1605
10:06 ET	129986	0.1609
10:08 ET	53328	0.1613
10:10 ET	44643	0.1608
10:12 ET	72701	0.1606
10:14 ET	308499	0.15915
10:15 ET	277203	0.159568
10:17 ET	81195	0.1601
10:19 ET	127487	0.1604
10:21 ET	175943	0.1625
10:24 ET	76611	0.1625
10:26 ET	109560	0.1639
10:28 ET	33543	0.1634
10:30 ET	148119	0.1652
10:32 ET	13463	0.1638
10:33 ET	30617	0.1645
10:35 ET	18334	0.1642
10:37 ET	39865	0.165004
10:39 ET	45942	0.1653
10:42 ET	85116	0.166504
10:44 ET	77115	0.166801
10:46 ET	98070	0.1669
10:48 ET	33987	0.1668
10:50 ET	28736	0.16675
10:51 ET	36380	0.1666
10:53 ET	54561	0.16665
10:55 ET	26920	0.166699
10:57 ET	53558	0.1667
11:00 ET	11833	0.1667
11:02 ET	190593	0.17
11:04 ET	204841	0.17195
11:06 ET	184840	0.1699
11:08 ET	213938	0.1717
11:09 ET	226712	0.1707
11:11 ET	83244	0.16995
11:13 ET	82226	0.17
11:15 ET	16187	0.1699
11:18 ET	117575	0.1684
11:20 ET	15152	0.1695
11:22 ET	60819	0.168
11:24 ET	63070	0.168
11:26 ET	12426	0.168117
11:27 ET	14021	0.1681
11:29 ET	12984	0.1686
11:31 ET	36818	0.1687
11:33 ET	192289	0.1681
11:36 ET	70374	0.167001
11:38 ET	38567	0.167351
11:40 ET	76305	0.166999
11:42 ET	4867	0.166997
11:44 ET	84095	0.1667
11:45 ET	8677	0.1668
11:47 ET	100096	0.1681
11:49 ET	29335	0.168696
11:51 ET	85233	0.16995
11:54 ET	189683	0.17
11:56 ET	63803	0.170499
11:58 ET	46374	0.1704
12:00 ET	179575	0.1704
12:02 ET	17229	0.1705
12:03 ET	274008	0.1732
12:05 ET	169317	0.1722
12:07 ET	23305	0.172
12:09 ET	100240	0.1725
12:12 ET	24111	0.1724
12:14 ET	443968	0.177
12:16 ET	357069	0.1768
12:18 ET	285941	0.1765
12:20 ET	88874	0.175999
12:21 ET	86916	0.175701
12:23 ET	174371	0.175
12:25 ET	85642	0.175201
12:27 ET	25242	0.1755
12:30 ET	158155	0.1757
12:32 ET	110438	0.1763
12:34 ET	17175	0.1757
12:36 ET	132045	0.1757
12:38 ET	16670	0.1759
12:39 ET	43828	0.1758
12:41 ET	19099	0.175
12:43 ET	123677	0.1735
12:45 ET	34575	0.173
12:48 ET	121402	0.173
12:50 ET	38599	0.172505
12:52 ET	75342	0.1726
12:54 ET	13456	0.1729
12:56 ET	5621	0.173
12:57 ET	79364	0.1731
12:59 ET	18829	0.173801
01:01 ET	14145	0.1738
01:03 ET	19846	0.17385
01:06 ET	13706	0.1733
01:08 ET	7350	0.1736
01:10 ET	26333	0.1734
01:12 ET	166519	0.173
01:14 ET	55676	0.172

Data delayed at least 15 minutes.

Apr 22, 2024
- Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company's Expanding Focus on Cancer Supportive Care, from 8:46AM ET on Monday Apr 22, 2024 by Dow Jones
  8:46AM ET on Monday Apr 22, 2024 by Dow Jones
Apr 18, 2024
- Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care, from 8:41AM ET on Thursday Apr 18, 2024 by Dow Jones
  8:41AM ET on Thursday Apr 18, 2024 by Dow Jones
Apr 16, 2024
- Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care, from 8:32AM ET on Tuesday Apr 16, 2024 by Dow Jones
  8:32AM ET on Tuesday Apr 16, 2024 by Dow Jones
Apr 9, 2024
- Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders, from 4:17PM ET on Tuesday Apr 09, 2024 by Dow Jones
  4:17PM ET on Tuesday Apr 09, 2024 by Dow Jones
Apr 8, 2024
- Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement, from 8:32AM ET on Monday Apr 08, 2024 by Dow Jones
  8:32AM ET on Monday Apr 08, 2024 by Dow Jones

0 New Today

Industry Peers Overview Table
Company sortable	Market Cap sortable	P/E Ratio (TTM) sortable	EPS Growth (5yr) sortable
United StatesJAGX Jaguar Health Inc	46.9M	0.0x	---
United StatesAWH Aspira Women's Health Inc	42.0M	-1.9x	---
United StatesBOLT Bolt Biotherapeutics Inc	45.8M	-0.6x	---
United StatesIKNA Ikena Oncology Inc	62.3M	-0.8x	---
United StatesSPRB Spruce Biosciences Inc	28.9M	-0.5x	---
United StatesCLGN Collplant Biotechnologies Ltd	62.0M	-8.5x	---
As of 2024-04-25

Jaguar Health, Inc. is a commercial-stage pharmaceuticals company. The Company is focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. It operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. The Canalevia-CA1 is for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Its subsidiary Napo Pharmaceuticals, Inc. focuses on developing and commercializing human prescription pharmaceuticals.

Contact Information

Headquarters: 200 PINE STREET SUITE 400SAN FRANCISCO, CA, United States 94104
Phone: 415-371-8300
Fax: 302-655-5049

Executives

Independent Chairman of the Board: James Bochnowski
President, Chief Executive Officer, Director: Lisa Conte
Chief Financial Officer: Carol Lizak
Chief Scientific Officer: Pravin Chaturvedi
Chief of Staff, General Counsel, Chief Compliance Officer: Jonathan Wolin

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Skip section

INK Company InsiderDetailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®.

Fundamentals Table
Market Cap	$46.9M
Revenue (TTM)	$9.8M
Shares Outstanding	276.2M
Dividend Yield	0.00%
Annual Dividend Rate	---
Ex-Dividend Date	01-01-01
Pay Date	01-01-01
Beta	1.10
EPS	$-3.64
Book Value	$0.07
P/E Ratio	0.0x
Price/Sales (TTM)	4.8
Price/Cash Flow (TTM)	---
Operating Margin	-313.43%

*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Jaguar Health Inc
NASDAQ:JAGXUnited States
NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Search Criteria

Charts

Recent News

Apr 22, 2024

Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company's Expanding Focus on Cancer Supportive Care, from 8:46AM ET on Monday Apr 22, 2024 by Dow Jones

Apr 18, 2024

Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care, from 8:41AM ET on Thursday Apr 18, 2024 by Dow Jones

Apr 16, 2024

Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care, from 8:32AM ET on Tuesday Apr 16, 2024 by Dow Jones

Apr 9, 2024

Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders, from 4:17PM ET on Tuesday Apr 09, 2024 by Dow Jones

Apr 8, 2024

Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement, from 8:32AM ET on Monday Apr 08, 2024 by Dow Jones

Biotechnology Industry Peers

Company Information

Contact Information

Executives

Ratings

Reports

Fundamentals

Calendar